home / stock / czo:cc / czo:cc news

CZO:CC News and Press, Ceapro Inc. From 01/10/23

Stock Information
Company Name: Ceapro Inc.
Stock Symbol: CZO:CC
Market: TSXVC
Website: ceapro.com
Menu
CZO:CC CZO:CC Quote CZO:CC Short CZO:CC News CZO:CC Articles CZO:CC Message Board
Get CZO:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
CZO:CC - Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event

EDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic ind...
CZO:CC - Ceapro Announces Grant of Stock Options

EDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic ind...

CZO:CC - Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets

- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory - Clinical study to be conducted with the Montreal Heart Institute led by MHI’s Montreal Health Innovations Coordinating Center (MHICC) EDMONTON, Alberta, Dec. 22, 2022 (GLOBE NEWSWIRE...

CZO:CC - Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights

– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology – Q3 2022 sales of $3,845,000 vs $4,523,000 in Q3 2021 ; YTD sales increase 14% vs 2021 - $15,517,000 vs $13,633,000 ...
CZO:CC - Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

PGX processing unit to be installed at Agri-Food Discovery Place of University of Alberta Alginate and yeast beta glucan to be the first bio actives to be processed at this location EDMONTON, Alberta, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO;...

CZO:CC - Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

Findings from this collaborative project with the University of Alberta using a unique surgical methodology illustrate how PGX-processed carriers can successfully be uniformly loaded with a fat-soluble active ingredient to generate superior bioactive delivery systems Superior bi...

CZO:CC - Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update

– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a 25% increase – YTD Sales increased 28% vs 2021 – $11,672,000 vs $9,110,000 – Income before tax of $2,177,000 in Q2 2022 vs $676,...
CZO:CC - Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis

– Continuation of research with McMaster University to validate the anti-fibrotic properties of the Company’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and to pave the way for Phase 1 clinical trial EDMONTON, Alberta, Aug. 11, 2022 (GLOB...

CZO:CC - Ceapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue Officer

Recognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company towards next phase of growth EDMONTON, Alberta, July 12, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: ...

CZO:CC - Ceapro Announces Results of 2022 Shareholders' Meeting

EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and co...
Previous 10 Next 10